RayKnowChina Research Map
Shortlist0

RecruitingOesophageal squamous cell carcinomaHepatocellular carcinomaStomach cancerPhase 1

Registered title, quoted from ClinicalTrials.gov

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

An open trial on oesophageal squamous cell carcinoma and hepatocellular carcinoma and stomach cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 3 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 3

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteBeijing Friendship Hospital首都医科大学附属北京友谊医院BeijingHospital page
  2. Study sitePeking University Cancer Hospital北京大学肿瘤医院BeijingHospital page
  3. Study siteShanghai East Hospital, Tongji University同济大学附属东方医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05208762, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Participants must have one of the following histologically- or cytologically-confirmed metastatic or unresectable solid tumor types

    Inclusion criterion 2

    Participants with HNSCC must have histologically or cytologically-confirmed HNSCC

    Inclusion criterion 12

    Participants must have histologically or cytologically-confirmed NSCLC. Participants with SCC and non--SCC histology are eligible. Note: Participants with a neuroendocrine component or histology are not eligible.

    Inclusion criterion 14

    Participants must have histologically or cytologically-confirmed disease of the HNSCC or NSCLC

    Inclusion criterion 23

  3. And are off of corticosteroids prescribed for symptoms associate with brain metastases for at least 7 days prior to first dose of study treatment

    Exclusion criterion 5

    Prior treatment with an anti-PD-L1 agent within less than 5 half-lives. This duration of time will vary according to the half-life of the specific agent.

    Exclusion criterion 7

  4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1

    Inclusion criterion 27

  5. Measurable disease per RECIST v1.1 at baseline

    Inclusion criterion 28

  6. History of another malignancy within 3 years of first dose of study treatment or any evidence of residual disease from a previously diagnosed malignancy.

    Exclusion criterion 1

    Pre-existing neuropathy ≥Grade 2 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0.

    Exclusion criterion 9

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05208762, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Parts A and B:
  • Participants must have one of the following histologically- or cytologically-confirmed metastatic or unresectable solid tumor types
  • Non-small cell lung cancer (NSCLC)
  • Head and neck squamous cell carcinoma (HNSCC) (except nasopharyngeal cancer)
  • Esophageal squamous cell carcinoma (SCC)
  • Triple negative breast cancer (TNBC)
  • Participants must have disease that is relapsed or refractory, that has progressed on approved therapies, be intolerant to or refused such therapies, or such and therapies are contraindicated and in the judgement of the investigator, should have no appropriate SoC therapeutic option
  • Participants must have PD-L1 expression based on historical testing
  • Part C:
  • Participants must have disease that is relapsed or refractory or be intolerant to SoC therapies and must have one of the following tumor types
  • HNSCC
  • Participants with HNSCC must have histologically or cytologically-confirmed HNSCC
  • NSCLC
  • Participants must have histologically or cytologically-confirmed NSCLC. Participants with SCC and non--SCC histology are eligible. Note: Participants with a neuroendocrine component or histology are not eligible.
  • Esophageal SCC
  • Pancreatic cancer
  • Hepatocellular carcinoma
  • TNBC
  • Gastric cancer
  • Endometrial cancer
  • Participants must have been previously tested for PD-L1 expression and should have PD-L1 expression ≥1 or <1 by CPS or TPS based on historical testing
  • Part D and Part E:
  • Participants must have histologically or cytologically-confirmed disease of the HNSCC or NSCLC
  • Participants must have PD-L1 expression based on historical testing
  • Participants with NSCLC; PD-L1 expression ≥ 1% by TPS
  • Participants with HNSCC; PD--L1 expression ≥1 by CPS
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
  • Measurable disease per RECIST v1.1 at baseline

Exclusion Criteria:

  • History of another malignancy within 3 years of first dose of study treatment or any evidence of residual disease from a previously diagnosed malignancy.
  • Known active central nervous system metastases. Participants with previously-treated brain metastases may participate provided they:
  • Are clinically stable for at least 4 weeks prior to study entry after brain metastasis treatment
  • Have no new or enlarging brain metastases
  • And are off of corticosteroids prescribed for symptoms associate with brain metastases for at least 7 days prior to first dose of study treatment
  • Lepto-meningeal disease
  • Prior treatment with an anti-PD-L1 agent within less than 5 half-lives. This duration of time will vary according to the half-life of the specific agent.
  • Previous receipt of an monomethylauristatin E (MMAE)-containing agent.
  • Pre-existing neuropathy ≥Grade 2 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0.

There are additional inclusion criteria. The study center will determine if criteria for participations are met.

Quoted from ClinicalTrials.gov, NCT05208762, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05208762, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05208762